MX2021006111A - Composicion farmaceutica que comprende un anticuerpo anti-gm-csf para usarse en el tratamiento de artritis reumatoide. - Google Patents

Composicion farmaceutica que comprende un anticuerpo anti-gm-csf para usarse en el tratamiento de artritis reumatoide.

Info

Publication number
MX2021006111A
MX2021006111A MX2021006111A MX2021006111A MX2021006111A MX 2021006111 A MX2021006111 A MX 2021006111A MX 2021006111 A MX2021006111 A MX 2021006111A MX 2021006111 A MX2021006111 A MX 2021006111A MX 2021006111 A MX2021006111 A MX 2021006111A
Authority
MX
Mexico
Prior art keywords
rheumatoid arthritis
treatment
csf antibodies
mor103
dosages
Prior art date
Application number
MX2021006111A
Other languages
English (en)
Inventor
Stefan Steidl
Stefan Haertle
Stephane Leclair
Amgad Shebl
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of MX2021006111A publication Critical patent/MX2021006111A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención proporciona anticuerpos anti-GM-CSF para usarse en el tratamiento de artritis reumatoide. Los anticuerpos anti-GM-CSF, en particular MOR103, se administran a los pacientes que padezcan de artritis reumatoide en dosificaciones que sean benéficas en una situación clínica.
MX2021006111A 2012-09-20 2015-03-20 Composicion farmaceutica que comprende un anticuerpo anti-gm-csf para usarse en el tratamiento de artritis reumatoide. MX2021006111A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12185235 2012-09-20
US201261703871P 2012-09-21 2012-09-21

Publications (1)

Publication Number Publication Date
MX2021006111A true MX2021006111A (es) 2021-07-07

Family

ID=46963526

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015003644A MX2015003644A (es) 2012-09-20 2013-09-19 Tratamiento para artritis reumatoide.
MX2021006111A MX2021006111A (es) 2012-09-20 2015-03-20 Composicion farmaceutica que comprende un anticuerpo anti-gm-csf para usarse en el tratamiento de artritis reumatoide.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015003644A MX2015003644A (es) 2012-09-20 2013-09-19 Tratamiento para artritis reumatoide.

Country Status (23)

Country Link
US (3) US20150246969A1 (es)
EP (3) EP3916013A1 (es)
JP (3) JP2015533806A (es)
KR (3) KR20230041086A (es)
CN (2) CN104995210A (es)
AU (2) AU2013320261A1 (es)
BR (1) BR112015006189B1 (es)
CA (1) CA2884124A1 (es)
CL (2) CL2015000696A1 (es)
CR (1) CR20150153A (es)
DO (1) DOP2015000070A (es)
EA (1) EA031489B1 (es)
HK (1) HK1208231A1 (es)
IL (1) IL237554B (es)
IN (1) IN2015KN00657A (es)
MA (1) MA37946B1 (es)
MX (2) MX2015003644A (es)
MY (1) MY175388A (es)
PE (1) PE20151079A1 (es)
PH (1) PH12015500591A1 (es)
SG (2) SG11201501595YA (es)
UA (1) UA117228C2 (es)
WO (1) WO2014044768A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3916013A1 (en) * 2012-09-20 2021-12-01 MorphoSys AG Treatment for rheumatoid arthritis with anti-gm-csf antibody
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
US9833410B2 (en) 2012-10-31 2017-12-05 Takeda Gmbh Lyophilized formulation comprising GM-CSF neutralizing compound
WO2015028657A1 (en) 2013-08-30 2015-03-05 Takeda Gmbh Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics
US11299528B2 (en) * 2014-03-11 2022-04-12 D&D Pharmatech Inc. Long acting TRAIL receptor agonists for treatment of autoimmune diseases
US11173208B2 (en) * 2014-05-07 2021-11-16 Takeda Gmbh Liquid formulation comprising GM-CSF neutralizing compound
GB201519331D0 (en) * 2015-11-02 2015-12-16 Glaxosmithkline Ip Dev Ltd Treatment paradigm
CA3008392C (en) 2015-12-17 2021-11-09 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
CA3020339C (en) 2016-04-07 2022-05-03 The Johns Hopkins University Compositions and methods for treating pancreatitis and pain with death receptor agonists
BR112019005274A2 (pt) * 2016-09-19 2019-06-04 I Mab anticorpo isolado ou fragmento do mesmo, composição, célula isolada, e, métodos para tratar uma doença ou condição inflamatória ou autoimune, para tratar um câncer, para reduzir ou aliviar dor e para detectar expressão de gm-csf em uma amostra.
US11655293B2 (en) * 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
EP3623382A1 (en) 2018-09-14 2020-03-18 Universität Zürich Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
WO2021204649A1 (en) 2020-04-06 2021-10-14 Glaxosmithkline Intellectual Property Development Limited Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
KR100408229B1 (ko) 1996-10-04 2003-12-01 암겐 인코포레이티드 Ｍｐｌ 리간드를 함유하는 제약학적 조성물
US7455836B2 (en) 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
NZ564027A (en) * 2005-05-18 2011-06-30 Morphosys Ag Anti-GM-CSF antibodies and uses therefor
WO2007037795A2 (en) 2005-08-05 2007-04-05 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
US9399061B2 (en) * 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
WO2008042261A2 (en) * 2006-09-28 2008-04-10 Elusys Therapeutics, Inc. Anti-anthrax antibody, formulations thereof, and methods of use
NZ598345A (en) * 2006-11-21 2013-09-27 Kalobios Pharmaceuticals Inc Methods of treating chronic inflammatory diseases using a gm-csf antagonist
RU2491094C2 (ru) * 2007-03-30 2013-08-27 Медиммун, Ллк Препарат антитела
WO2008122007A1 (en) * 2007-04-02 2008-10-09 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
AU2008235044B2 (en) 2007-04-05 2011-08-25 Sandoz Ag Stable aqueous G-CSF formulations
US20090004189A1 (en) * 2007-06-18 2009-01-01 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
ES2401536T3 (es) * 2007-11-13 2013-04-22 Evec Inc. Anticuerpos monoclonales que se unen a HGM-CSF y composiciones medicinales que los comprenden
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
US8475796B2 (en) 2008-12-22 2013-07-02 University Of Melbourne Method of treating pain using an antagonist of GM-CSF
CN106397591A (zh) 2008-12-22 2017-02-15 墨尔本大学 骨关节炎治疗
JP2010241718A (ja) 2009-04-03 2010-10-28 Kyowa Hakko Kirin Co Ltd 安定な抗体の水溶液製剤
US20120116059A1 (en) * 2009-05-05 2012-05-10 Morphosys Ag Treatment For M Treatment For Multiple Sclerosis
PT2341061E (pt) 2009-12-31 2013-11-05 Arven Ilac Sanayi Ve Ticaret As Um processo novo para a preparação de g-csf (fator de estimulação de colónias de granulócitos)
NZ602685A (en) * 2010-03-01 2014-10-31 Cytodyn Inc Concentrated protein formulations and uses thereof
CA2839513A1 (en) 2011-07-06 2013-01-10 Morphosys Ag Therapeutic combinations of anti - cd20 and anti - gm - csf antibodies and uses thereof
EP3916013A1 (en) * 2012-09-20 2021-12-01 MorphoSys AG Treatment for rheumatoid arthritis with anti-gm-csf antibody

Also Published As

Publication number Publication date
JP2015533806A (ja) 2015-11-26
CL2015000696A1 (es) 2015-10-23
SG10201803778PA (en) 2018-06-28
BR112015006189B1 (pt) 2022-04-05
EP3345923A1 (en) 2018-07-11
JP2018138551A (ja) 2018-09-06
IL237554B (en) 2019-12-31
PE20151079A1 (es) 2015-08-07
US20150246969A1 (en) 2015-09-03
MA37946B1 (fr) 2018-09-28
PH12015500591B1 (en) 2015-05-11
AU2016250388A1 (en) 2016-11-17
CL2018000933A1 (es) 2018-07-20
MA37946A1 (fr) 2018-01-31
HK1208231A1 (en) 2016-02-26
PH12015500591A1 (en) 2015-05-11
AU2016250388B2 (en) 2018-07-19
CR20150153A (es) 2015-09-14
EA201590359A1 (ru) 2015-08-31
MX2015003644A (es) 2015-09-25
CN104995210A (zh) 2015-10-21
BR112015006189A2 (pt) 2019-11-26
DOP2015000070A (es) 2015-08-16
MY175388A (en) 2020-06-23
SG11201501595YA (en) 2015-05-28
EP3916013A1 (en) 2021-12-01
KR20150056846A (ko) 2015-05-27
AU2013320261A1 (en) 2015-04-09
EA031489B1 (ru) 2019-01-31
US10913792B2 (en) 2021-02-09
CA2884124A1 (en) 2014-03-27
EP2897977A1 (en) 2015-07-29
KR20230041086A (ko) 2023-03-23
WO2014044768A1 (en) 2014-03-27
CN109999195A (zh) 2019-07-12
IL237554A0 (en) 2015-04-30
KR20220028177A (ko) 2022-03-08
UA117228C2 (uk) 2018-07-10
US20210130451A1 (en) 2021-05-06
US20180230208A1 (en) 2018-08-16
IN2015KN00657A (es) 2015-07-17
JP2022169709A (ja) 2022-11-09

Similar Documents

Publication Publication Date Title
MX2021006111A (es) Composicion farmaceutica que comprende un anticuerpo anti-gm-csf para usarse en el tratamiento de artritis reumatoide.
IL276434A (en) Combined treatment involving antibodies against claudin 18.2 for the treatment of cancer
IL279330A (en) Combined treatment including antibodies against Claudin 18.2 for the treatment of cancer
MX342810B (es) Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso.
NZ630542A (en) Methods of treating a tauopathy
MX2020010693A (es) Uso de peptidos glp-1 de accion prolongada.
UA113403C2 (xx) Спосіб підвищення ефективності folr1 терапії раку
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep
MX2017003216A (es) Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica.
ME02932B (me) Kombinovana terapija koja uključuje antitela protiv klaudina 18.2 za lečenje kancera
MX2013003168A (es) Anticuerpo contra ephrin b2 y su uso.
MX2019008148A (es) Uso de peptidos glp-1 de accion prolongada.
TN2013000068A1 (en) Anti-vegfr-3 antibody compositions
UA97054C2 (ru) Способ комплексного лечения больных с зависимостью вследствие употребления психоактивных веществ
UA74882U (uk) Фармацевтична композиція для лікування сексуальної дисфункції